Dermatology Times, July 1st, 2003
Electochemotherapy with low-dose interleukin-2 active in disseminated malignant melanoma
Chicago - Results from an ongoing phase II clinical trial point out that electrochemotherapy followed by low-dose interleukin-2 (IL-2) (Proleukin) produces a clinical response in a subset of patients with disseminated malignant melanoma, Julie Gehl, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.
"We see systemic immune responses using a simple outpatient treatment with electrochemotherapy followed by low-dose IL-2 given subcutaneously at two million units per day," sa...
HighBeam Research, Free Preview: 'Antigen activation'... Full Membership required for unlimited access. Free 7-day trial.
Subscribers: HighBeam content is only available to HighBeam subscribers. Click the link above for more information.
